Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2020 | The future of CLL treatment: chemotherapy and targeted inhibitors

Catherine Wu • 7 Oct 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Catherine Wu, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the future of treatment in chronic lymphocytic leukemia (CLL). In the past chemotherapy and individual target inhibitors have been explored. Now the combination of both is being investigated for effect tumour eliminating therapies with limited toxicity. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

Disclosures

Catherine Wu, MD, holds equity in BionTech, Inc; and receives research funding from Pharmacyclics.

More from Catherine Wu

2:13
CLL at a genomic level
Catherine Wu • 7 Oct 2020
1:59
Relapse after stem cell transplant: differences in leukemic cells
Catherine Wu • 7 Oct 2020

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals